The European Patent Office (EPO) has published a new patent application, EP4467195A2, related to therapeutic agents for neurodegenerative diseases. The application, filed by IntraBio Ltd., specifies chemical compounds such as A61K 31/13 and A61K 31/495, and their use in treating conditions classified under A61P 25/00. This publication represents a new entry in the patent landscape for treatments in this therapeutic area.

This patent publication does not impose direct compliance obligations on regulated entities. However, it is relevant for pharmaceutical companies and drug manufacturers involved in research and development of treatments for neurodegenerative diseases. Companies operating in this space should be aware of this patent filing as it may impact their intellectual property strategy and freedom to operate in the development of similar therapeutic agents.